References
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362, 1907–1917 (2003).
- El-Serag HB, Marrero JA, Rudolph L et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology134, 1752–1763 (2008).
- Treiber G. Systemic treatment of hepatocellular carcinoma. Dig. Dis.19, 311–323 (2001).
- Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol.48(Suppl. 1), S20–S37 (2008).
- Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24, 4293–4300 (2006).
- Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol.25, LBA1 (2007).
- Cheng A, Kang Y, Chen Z et al. Randomized Phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J. Clin. Oncol.26, (2008) (Abstract 4509).
- Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J. Gastroenterol.13, 5845–5856 (2007).
- Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology72(Suppl. 1), 30–44 (2007).
- Kopelovich L, Fay JR, Sigman CC et al. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev.16, 1330–1340 (2007).
- Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene25, 6347–6360 (2006).
- Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer4, 335–348 (2004).
- Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene25, 6436–6446 (2006).
- Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov.5, 671–688 (2006).
- Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell12, 9–22 (2007)
- Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv. Exp. Med. Biol.587, 309–327 (2006).
- Seeliger H, Guba M, Kleespies A et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev.26, 611–621 (2007).
- Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs17, 487–494 (2006).
- Easton JB, Kurmasheva RT, Houghton PJ. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell9, 153–155 (2006).
- Sahin F, Kannangai R, Adegbola O et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res.10, 8421–8425 (2004).
- Sieghart W, Fuereder T, Schmid K et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation83, 425–432 (2007).
- Baba HA, Wohlschlaeger J, Cicinnati VR et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. DOI: 10.1111/j.1478-3231.2008.01798.x (2008) (Epub ahead of print).
- Villanueva A, Chiang DY, Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology135(6), 1972–1983 (2008).
- Schmitz KJ, Wohlschlaeger J, Lang H et al. Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol.48, 83–90 (2008).
- Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs14, 313–328 (2005).
- Huynh H, Chow KP, Soo KC et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. DOI: 10.1111/j.1582-4934.2008.00364.x (2008) (Epub ahead of print).
- Rizell M, Lindner P. Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res.25, 789–793 (2005).
- Schumacher G, Oidtmann M, Rueggeberg A et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J. Gastroenterol.11, 1420–1425 (2005).
- Semela D, Piguet AC, Kolev M et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol.46, 840–848 (2007).
- Piguet AC, Semela D, Keogh A et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J. Hepatol.49, 78–87 (2008).
- Watson CJ, Friend PJ, Jamieson NV et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation67, 505–509 (1999).
- Chang GJ, Mahanty HD, Quan D et al. Experience with the use of sirolimus in liver transplantation – use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl.6, 734–740 (2000).
- Toso C, Meeberg GA, Bigam DL et al.De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation83, 1162–1168 (2007).
- Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl.10, 1301–1311 (2004).
- Zhou J, Fan J, Wang Z et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J. Gastroenterol.12, 3114–3118 (2006).
- Zimmerman MA, Trotter JF, Wachs M et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl. Int.20, 747–753 (2007).
- Zimmerman MA, Trotter JF, Wachs M et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl.14, 633–638 (2008).
- Chen YB, Sun YA, Gong JP. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat. Dis. Int.7, 25–28 (2008).
- Rizell M, Andersson M, Cahlin C et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J. Clin. Oncol.13, 66–70 (2008).
- Decaens T, Luciani A, Itti E et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Hepatology48(Suppl.), 953A (2008) (Abstract 1453).
- Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol.26(18), 2992–2998 (2008).
- Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J. Cancer Res. Clin. Oncol.135(2), 271–281 (2009).
- Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology48(4), 1312–1327 (2008).
- Thomas MB, Chadha R, Glover K et al. Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer110(5), 1059–1067 (2007).
- Treiber G, Wex T, Rocken C et al. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.132, 699–708 (2006).
- Newell P, Roayaie S, Schwartz M et al. Mechanisms of Ras pathway activation in HCC patients, and combination therapies blocking Ras (sorafenib) and mTOR pathways (rapamycin) in vivo. Hepatology48(Suppl.), 983A (2008) (Abstract 1521).
- Attia S, Holen KD, Thomas JP et al. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin. Adv. Hematol. Oncol.6, 44–54 (2008).
- Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst.100, 698–711 (2008).
Websites
- SiLVER Study: for patients with hepatocellular carcinoma undergoing liver transplantation www.silver-study.org
- NCT00390195 http://clinicaltrials.gov/ct2/show/nct00390195?term=nct00390195&rank=1
- NCT00516165 http://clinicaltrials.gov/ct2/show/nct00516165?term=nct00516165&rank=1
- NCT00554125 http://clinicaltrials.gov/ct2/show/nct00554125?term=nct00554125&rank=1
- NCT00355862 http://clinicaltrials.gov/ct2/show/nct00355862?term=nct00355862&rank=1
- NCT00467194 http://clinicaltrials.gov/ct2/show/nct00467194?term=nct00467194&rank=1
- NCT00775073 http://clinicaltrials.gov/ct2/show/nct00775073?term=nct00775073&rank=1
- NCT00328770 http://clinicaltrials.gov/ct2/show/nct00328770?term=nct00328770&rank=1
- NCT00375245 http://clinicaltrials.gov/ct2/show/nct00375245?term=nct00375245&rank=1